Goldenrod Therapeutics
Summary active Updated Jun 9, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Goldenrod Therapeutics is a Houston-based biotechnology company developing 11h, a next-generation orally bioavailable, brain-penetrant PDE4 inhibitor with potential as a best-in-class therapy for Friedreich’s Ataxia and a foundation for multiple neurodegenerative and neuroinflammatory disorders 12. The 11h technology was in-licensed from the University of Nebraska Medical Center (UNMC), where it was developed by Dr. Corey Hopkins 12. Proceeds from the seed round will fund manufacturing, formulation optimization, IND-enabling studies, and a Phase I study in Friedreich’s Ataxia 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-08 | Seed | $6.5M | Ataxia Ventures, Fannin Partners | 12 |
What Investors Say
“The scientific foundation established at [UNMC] and Fannin has positioned 11h as a potentially important advancement in CNS-targeted PDE4 inhibition.”
— Tom Hamilton, Ataxia Ventures 2
What Founders Say
No independently sourced founder testimonials found at time of research.
Sources
-
Finsmes, “Goldenrod Therapeutics Holds Initial Close of $6.5M Seed Funding,” June 8, 2026. Accessed June 2026. https://www.finsmes.com/2026/06/goldenrod-therapeutics-raises-6-5m-in-initial-close-of-series-seed-funding.html↩↩↩↩
-
UNeMed, “Hopkins molecule moves closer to clinic, startup raises $6.5 million,” June 2026. Accessed June 2026. https://www.unemed.com/news/goldenrod-raises-6-million↩↩↩↩
-
Business Wire, “Stock Sale Powers Goldenrod into Clinic with 11h program Targeting Brain Inflammation,” June 4, 2026. Accessed June 2026. https://www.businesswire.com/news/home/20260604274576/en/Stock-Sale-Powers-Goldenrod-into-Clinic-with-11h-program-Targeting-Brain-Inflammation↩